Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract their harmful molecular effects.

Bionyra Pharma has emerged with a $165 million oversubscribed series A and a portfolio of three antibodies with extended half ...

J-Pharma Co. Ltd. is progressing the most clinically advanced L-type amino acid transport 1 (LAT1) inhibitor, nanvuranlat ...

An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue. Investors are betting that a deeper ...

MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ...

SK Biopharmaceuticals Co. Ltd. is doubling down on AI-powered drug discovery through a new collaboration with Insilico ...

China’s National Medical Products Administration approved Carsgen Therapeutics Holdings Ltd.’s NDA for satricabtagene ...

The EMA’s 2025 annual report highlights the pressure it is under to streamline and simplify assessment processes, and the ...

Memento Medicines Inc. has announced its launch with a $93 million series A financing and the licensing of a lead program for ...

Harnessing an oncolytic signal and redirecting it against the tumor itself could be developed as a selective strategy for ...

The U.S. FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously in favor of Moderna Inc.’s ...